ID   PADI4_HUMAN             Reviewed;         663 AA.
AC   Q9UM07; A8K392; B2RBW0; Q5VTZ8; Q70SX4;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   22-JUL-2015, entry version 136.
DE   RecName: Full=Protein-arginine deiminase type-4;
DE            EC=3.5.3.15;
DE   AltName: Full=HL-60 PAD;
DE   AltName: Full=Peptidylarginine deiminase IV;
DE   AltName: Full=Protein-arginine deiminase type IV;
GN   Name=PADI4; Synonyms=PAD4, PADI5, PDI5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-55; ALA-82 AND ALA-112.
RX   PubMed=10488123; DOI=10.1074/jbc.274.39.27786;
RA   Nakashima K., Hagiwara T., Ishigami A., Nagata S., Asaga H.,
RA   Kuramoto M., Senshu T., Yamada M.;
RT   "Molecular characterization of peptidylarginine deiminase in HL-60
RT   cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3).";
RL   J. Biol. Chem. 274:27786-27792(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-275.
RX   PubMed=15087120; DOI=10.1016/j.gene.2003.12.038;
RA   Chavanas S., Mechin M.-C., Takahara H., Kawada A., Nachat R.,
RA   Serre G., Simon M.;
RT   "Comparative analysis of the mouse and human peptidylarginine
RT   deiminase gene clusters reveals highly conserved non-coding segments
RT   and a new human gene, PADI6.";
RL   Gene 330:19-27(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-55; ALA-82
RP   AND ALA-112.
RC   TISSUE=Pancreas, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11435484;
RA   Asaga H., Nakashima K., Senshu T., Ishigami A., Yamada M.;
RT   "Immunocytochemical localization of peptidylarginine deiminase in
RT   human eosinophils and neutrophils.";
RL   J. Leukoc. Biol. 70:46-51(2001).
RN   [7]
RP   INVOLVEMENT IN RA.
RX   PubMed=12833157; DOI=10.1038/ng1206;
RA   Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M.,
RA   Nagasaki M., Nakayama-Hamada M., Kawaida R., Ono M., Ohtsuki M.,
RA   Furukawa H., Yoshino S., Yukioka M., Tohma S., Matsubara T.,
RA   Wakitani S., Teshima R., Nishioka Y., Sekine A., Iida A.,
RA   Takahashi A., Tsunoda T., Nakamura Y., Yamamoto K.;
RT   "Functional haplotypes of PADI4, encoding citrullinating enzyme
RT   peptidylarginine deiminase 4, are associated with rheumatoid
RT   arthritis.";
RL   Nat. Genet. 34:395-402(2003).
RN   [8]
RP   FUNCTION.
RX   PubMed=15339660; DOI=10.1016/j.cell.2004.08.020;
RA   Cuthbert G.L., Daujat S., Snowden A.W., Erdjument-Bromage H.,
RA   Hagiwara T., Yamada M., Schneider R., Gregory P.D., Tempst P.,
RA   Bannister A.J., Kouzarides T.;
RT   "Histone deimination antagonizes arginine methylation.";
RL   Cell 118:545-553(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=15345777; DOI=10.1126/science.1101400;
RA   Wang Y., Wysocka J., Sayegh J., Lee Y.-H., Perlin J.R., Leonelli L.,
RA   Sonbuchner L.S., McDonald C.H., Cook R.G., Dou Y., Roeder R.G.,
RA   Clarke S., Stallcup M.R., Allis C.D., Coonrod S.A.;
RT   "Human PAD4 regulates histone arginine methylation levels via
RT   demethylimination.";
RL   Science 306:279-283(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.
RX   PubMed=15629448; DOI=10.1016/j.bbrc.2004.11.152;
RA   Nakayama-Hamada M., Suzuki A., Kubota K., Takazawa T., Ohsaka M.,
RA   Kawaida R., Ono M., Kasuya A., Furukawa H., Yamada R., Yamamoto K.;
RT   "Comparison of enzymatic properties between hPADI2 and hPADI4.";
RL   Biochem. Biophys. Res. Commun. 327:192-200(2005).
RN   [11]
RP   FUNCTION IN CITRULLINATION OF EP300.
RX   PubMed=15731352; DOI=10.1073/pnas.0407159102;
RA   Lee Y.-H., Coonrod S.A., Kraus W.L., Jelinek M.A., Stallcup M.R.;
RT   "Regulation of coactivator complex assembly and function by protein
RT   arginine methylation and demethylimination.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:3611-3616(2005).
RN   [12]
RP   FUNCTION.
RX   PubMed=18209087; DOI=10.4049/jimmunol.180.3.1895;
RA   Neeli I., Khan S.N., Radic M.;
RT   "Histone deimination as a response to inflammatory stimuli in
RT   neutrophils.";
RL   J. Immunol. 180:1895-1902(2008).
RN   [13]
RP   CITRULLINATION AT ARG-205; ARG-212; ARG-218; ARG-372; ARG-374 AND
RP   ARG-383.
RX   PubMed=20201080; DOI=10.1002/art.27439;
RA   Andrade F., Darrah E., Gucek M., Cole R.N., Rosen A., Zhu X.;
RT   "Autocitrullination of human peptidyl arginine deiminase type 4
RT   regulates protein citrullination during cell activation.";
RL   Arthritis Rheum. 62:1630-1640(2010).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH CALCIUM AND
RP   HISTONE H3 N-TERMINUS, X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN
RP   COMPLEX WITH CALCIUM AND HISTONE H4 N-TERMINUS, X-RAY CRYSTALLOGRAPHY
RP   (2.3 ANGSTROMS) IN COMPLEX WITH CALCIUM AND BENZOYL-ARGININE AMIDE,
RP   ACTIVE SITE, AND MUTAGENESIS OF ARG-374 AND CYS-645.
RX   PubMed=15247907; DOI=10.1038/nsmb799;
RA   Arita K., Hashimoto H., Shimizu T., Nakashima K., Yamada M., Sato M.;
RT   "Structural basis for Ca(2+)-induced activation of human PAD4.";
RL   Nat. Struct. Mol. Biol. 11:777-783(2004).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH CALCIUM AND
RP   HISTONE H3 AND H4 N-TERMINUS, COFACTOR, FUNCTION, CATALYTIC ACTIVITY,
RP   AND MUTAGENESIS OF ARG-374.
RX   PubMed=16567635; DOI=10.1073/pnas.0509639103;
RA   Arita K., Shimizu T., Hashimoto H., Hidaka Y., Yamada M., Sato M.;
RT   "Structural basis for histone N-terminal recognition by human
RT   peptidylarginine deiminase 4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5291-5296(2006).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH CALCIUM,
RP   COFACTOR, AND ENZYME REGULATION.
RX   PubMed=17002273; DOI=10.1021/bi061180d;
RA   Luo Y., Arita K., Bhatia M., Knuckley B., Lee Y.H., Stallcup M.R.,
RA   Sato M., Thompson P.R.;
RT   "Inhibitors and inactivators of protein arginine deiminase 4:
RT   functional and structural characterization.";
RL   Biochemistry 45:11727-11736(2006).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS), FUNCTION, CATALYTIC ACTIVITY,
RP   AND CHARACTERIZATION OF VARIANTS SER-55; ALA-82 AND ALA-112.
RX   PubMed=21245532; DOI=10.1107/S0907444910051711;
RA   Horikoshi N., Tachiwana H., Saito K., Osakabe A., Sato M., Yamada M.,
RA   Akashi S., Nishimura Y., Kagawa W., Kurumizaka H.;
RT   "Structural and biochemical analyses of the human PAD4 variant encoded
RT   by a functional haplotype gene.";
RL   Acta Crystallogr. D 67:112-118(2011).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH INHIBITOR,
RP   ENZYME REGULATION, AND MUTAGENESIS OF GLN-346; ARG-374 AND ARG-639.
RX   PubMed=21882827; DOI=10.1021/jm2008985;
RA   Causey C.P., Jones J.E., Slack J.L., Kamei D., Jones L.E.,
RA   Subramanian V., Knuckley B., Ebrahimi P., Chumanevich A.A., Luo Y.,
RA   Hashimoto H., Sato M., Hofseth L.J., Thompson P.R.;
RT   "The development of N-alpha-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-
RT   iminoethyl)-L-ornithine amide (o-F-amidine) and N-alpha-(2-
RT   Carboxyl)benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (o-Cl-
RT   amidine) as second generation protein arginine deiminase (PAD)
RT   inhibitors.";
RL   J. Med. Chem. 54:6919-6935(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.98 ANGSTROMS) IN COMPLEX WITH TDFA, AND
RP   ENZYME REGULATION.
RX   PubMed=22004374; DOI=10.1021/cb200258q;
RA   Jones J.E., Slack J.L., Fang P., Zhang X., Subramanian V.,
RA   Causey C.P., Coonrod S.A., Guo M., Thompson P.R.;
RT   "Synthesis and screening of a haloacetamidine containing library to
RT   identify PAD4 selective inhibitors.";
RL   ACS Chem. Biol. 7:160-165(2012).
RN   [20]
RP   VARIANTS ASN-89; THR-102 AND THR-131.
RX   PubMed=15338034; DOI=10.1007/s00109-004-0584-6;
RA   Hoppe B., Heymann G.A., Tolou F., Kiesewetter H., Doerner T.,
RA   Salama A.;
RT   "High variability of peptidylarginine deiminase 4 (PADI4) in a healthy
RT   white population: characterization of six new variants of PADI4 exons
RT   2-4 by a novel haplotype-specific sequencing-based approach.";
RL   J. Mol. Med. 82:762-767(2004).
CC   -!- FUNCTION: Catalyzes the citrullination/deimination of arginine
CC       residues of proteins such as histones, thereby playing a key role
CC       in histone code and regulation of stem cell maintenance.
CC       Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3
CC       at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci,
CC       H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3'
CC       (to form H4R3ci). Acts as a key regulator of stem cell maintenance
CC       by mediating citrullination of histone H1: citrullination of 'Arg-
CC       54' of histone H1 (H1R54ci) results in H1 displacement from
CC       chromatin and global chromatin decondensation, thereby promoting
CC       pluripotency and stem cell maintenance. Promotes profound
CC       chromatin decondensation during the innate immune response to
CC       infection in neutrophils by mediating formation of H1R54ci.
CC       Citrullination of histone H3 prevents their methylation by CARM1
CC       and HRMT1L2/PRMT1 and represses transcription. Citrullinates
CC       EP300/P300 at 'Arg-2142', which favors its interaction with
CC       NCOA2/GRIP1. {ECO:0000269|PubMed:15339660,
CC       ECO:0000269|PubMed:15345777, ECO:0000269|PubMed:15731352,
CC       ECO:0000269|PubMed:16567635, ECO:0000269|PubMed:18209087,
CC       ECO:0000269|PubMed:21245532}.
CC   -!- CATALYTIC ACTIVITY: Protein L-arginine + H(2)O = protein L-
CC       citrulline + NH(3). {ECO:0000269|PubMed:16567635,
CC       ECO:0000269|PubMed:21245532}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:15629448,
CC         ECO:0000269|PubMed:16567635, ECO:0000269|PubMed:17002273};
CC       Note=Binds 5 Ca(2+) ions per subunit.
CC       {ECO:0000269|PubMed:15629448, ECO:0000269|PubMed:16567635,
CC       ECO:0000269|PubMed:17002273};
CC   -!- ENZYME REGULATION: Strongly Inhibited by F-amidine and N-alpha-
CC       benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-amidine).
CC       These inhibitors are however not specific to PADI4 and also
CC       inhibit other members of the family (PubMed:17002273).
CC       Incorporation of a carboxylate ortho to the backbone amide of Cl-
CC       amidine results in inhibitors with increased specificity for
CC       PADI4: N-alpha-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-L-
CC       ornithine amide (o-F-amidine) and N-alpha-(2-carboxyl)benzoyl-
CC       N(5)-(2-chloro-1-iminoethyl)-L-ornithine amide (o-Cl-amidine)
CC       (PubMed:21882827). Strongly and specifically inhibited by Thr-Asp-
CC       F-amidine (TDFA); other members of the family are not inhibited
CC       (PubMed:22004374). {ECO:0000269|PubMed:17002273,
CC       ECO:0000269|PubMed:21882827, ECO:0000269|PubMed:22004374}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.055 mM for fibrinogen {ECO:0000269|PubMed:15629448};
CC         KM=0.064 mM for filaggrin {ECO:0000269|PubMed:15629448};
CC         Vmax=33.2 umol/h/mg enzyme toward fibrinogen
CC         {ECO:0000269|PubMed:15629448};
CC         Vmax=8.0 umol/h/mg enzyme toward filaggrin
CC         {ECO:0000269|PubMed:15629448};
CC       pH dependence:
CC         Optimum pH is 6.5-9.0. {ECO:0000269|PubMed:15629448};
CC   -!- INTERACTION:
CC       Q6LES2:ANXA4; NbExp=3; IntAct=EBI-1042511, EBI-10250835;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasmic granule.
CC       Note=Cytoplasmic granules of eosinophils and neutrophils.
CC   -!- TISSUE SPECIFICITY: Expressed in eosinophils and neutrophils, not
CC       expressed in peripheral monocytes or lymphocytes.
CC       {ECO:0000269|PubMed:11435484}.
CC   -!- PTM: Autocitrullination at Arg-372 and Arg-374 inactivates the
CC       enzyme.
CC   -!- DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory
CC       disease with autoimmune features and a complex genetic component.
CC       It primarily affects the joints and is characterized by
CC       inflammatory changes in the synovial membranes and articular
CC       structures, widespread fibrinoid degeneration of the collagen
CC       fibers in mesenchymal tissues, and by atrophy and rarefaction of
CC       bony structures. {ECO:0000269|PubMed:12833157}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC       The association to rheumatoid arthritis was initially thought to
CC       result from increased citrullination of target proteins
CC       (PubMed:12833157). However, variants that have been associated to
CC       rheumatoid arthritis (Ser-55, Ala-82 and Ala-112) do not affect
CC       the catalytic activity or the citrullination activity of PADI4,
CC       suggesting that these variants may affect the mRNA stability
CC       rather than the protein (PubMed:21245532).
CC       {ECO:0000269|PubMed:12833157, ECO:0000269|PubMed:21245532}.
CC   -!- SIMILARITY: Belongs to the protein arginine deiminase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB017919; BAA84542.1; -; mRNA.
DR   EMBL; AJ549502; CAE47743.1; -; Genomic_DNA.
DR   EMBL; AK290507; BAF83196.1; -; mRNA.
DR   EMBL; AK314839; BAG37357.1; -; mRNA.
DR   EMBL; AL590644; CAH73167.1; -; Genomic_DNA.
DR   EMBL; AC004824; CAH73167.1; JOINED; Genomic_DNA.
DR   EMBL; BC025718; AAH25718.1; -; mRNA.
DR   CCDS; CCDS180.1; -.
DR   RefSeq; NP_036519.2; NM_012387.2.
DR   UniGene; Hs.522969; -.
DR   PDB; 1WD8; X-ray; 2.80 A; A=1-663.
DR   PDB; 1WD9; X-ray; 2.60 A; A=1-663.
DR   PDB; 1WDA; X-ray; 2.30 A; A=1-663.
DR   PDB; 2DEW; X-ray; 2.10 A; X=1-663.
DR   PDB; 2DEX; X-ray; 2.10 A; X=1-663.
DR   PDB; 2DEY; X-ray; 2.25 A; X=1-663.
DR   PDB; 2DW5; X-ray; 2.30 A; A=1-663.
DR   PDB; 3APM; X-ray; 2.50 A; A=1-663.
DR   PDB; 3APN; X-ray; 2.70 A; A=1-663.
DR   PDB; 3B1T; X-ray; 2.50 A; A=1-663.
DR   PDB; 3B1U; X-ray; 2.10 A; A=1-663.
DR   PDB; 4DKT; X-ray; 2.98 A; A=1-663.
DR   PDB; 4X8C; X-ray; 3.10 A; A=1-663.
DR   PDB; 4X8G; X-ray; 3.29 A; A=1-663.
DR   PDBsum; 1WD8; -.
DR   PDBsum; 1WD9; -.
DR   PDBsum; 1WDA; -.
DR   PDBsum; 2DEW; -.
DR   PDBsum; 2DEX; -.
DR   PDBsum; 2DEY; -.
DR   PDBsum; 2DW5; -.
DR   PDBsum; 3APM; -.
DR   PDBsum; 3APN; -.
DR   PDBsum; 3B1T; -.
DR   PDBsum; 3B1U; -.
DR   PDBsum; 4DKT; -.
DR   PDBsum; 4X8C; -.
DR   PDBsum; 4X8G; -.
DR   DisProt; DP00321; -.
DR   ProteinModelPortal; Q9UM07; -.
DR   SMR; Q9UM07; 2-663.
DR   BioGrid; 117111; 10.
DR   DIP; DIP-50397N; -.
DR   IntAct; Q9UM07; 2.
DR   STRING; 9606.ENSP00000364597; -.
DR   BindingDB; Q9UM07; -.
DR   ChEMBL; CHEMBL6111; -.
DR   DrugBank; DB00207; Azithromycin.
DR   DrugBank; DB00254; Doxycycline.
DR   DrugBank; DB00155; L-Citrulline.
DR   DrugBank; DB01082; Streptomycin.
DR   DrugBank; DB00759; Tetracycline.
DR   PhosphoSite; Q9UM07; -.
DR   BioMuta; PADI4; -.
DR   DMDM; 296439260; -.
DR   PaxDb; Q9UM07; -.
DR   PRIDE; Q9UM07; -.
DR   DNASU; 23569; -.
DR   Ensembl; ENST00000375448; ENSP00000364597; ENSG00000159339.
DR   Ensembl; ENST00000628229; ENSP00000487021; ENSG00000280908.
DR   GeneID; 23569; -.
DR   KEGG; hsa:23569; -.
DR   UCSC; uc001baj.2; human.
DR   CTD; 23569; -.
DR   GeneCards; GC01P017634; -.
DR   H-InvDB; HIX0000182; -.
DR   HGNC; HGNC:18368; PADI4.
DR   HPA; HPA017007; -.
DR   HPA; HPA042825; -.
DR   MIM; 180300; phenotype.
DR   MIM; 605347; gene.
DR   neXtProt; NX_Q9UM07; -.
DR   PharmGKB; PA32903; -.
DR   eggNOG; NOG42085; -.
DR   GeneTree; ENSGT00390000008680; -.
DR   HOGENOM; HOG000220908; -.
DR   HOVERGEN; HBG053016; -.
DR   InParanoid; Q9UM07; -.
DR   KO; K01481; -.
DR   OMA; HVARSEM; -.
DR   OrthoDB; EOG7P5T09; -.
DR   PhylomeDB; Q9UM07; -.
DR   TreeFam; TF331952; -.
DR   BioCyc; MetaCyc:HS08389-MONOMER; -.
DR   BRENDA; 3.5.3.15; 2681.
DR   ChiTaRS; PADI4; human.
DR   EvolutionaryTrace; Q9UM07; -.
DR   GeneWiki; PADI4; -.
DR   GenomeRNAi; 23569; -.
DR   NextBio; 35463997; -.
DR   PRO; PR:Q9UM07; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; Q9UM07; -.
DR   CleanEx; HS_PADI4; -.
DR   ExpressionAtlas; Q9UM07; baseline and differential.
DR   Genevisible; Q9UM07; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016990; F:arginine deiminase activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004668; F:protein-arginine deiminase activity; IDA:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0016568; P:chromatin modification; ISS:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB.
DR   GO; GO:0036414; P:histone citrullination; IDA:UniProtKB.
DR   GO; GO:0036413; P:histone H3-R26 citrullination; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006334; P:nucleosome assembly; ISS:UniProtKB.
DR   GO; GO:0018101; P:protein citrullination; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0019827; P:stem cell maintenance; ISS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR008972; Cupredoxin.
DR   InterPro; IPR004303; PAD.
DR   InterPro; IPR013530; PAD_C.
DR   InterPro; IPR013732; PAD_N.
DR   InterPro; IPR013733; Prot_Arg_deaminase_cen_dom.
DR   PANTHER; PTHR10837; PTHR10837; 1.
DR   Pfam; PF03068; PAD; 1.
DR   Pfam; PF08527; PAD_M; 1.
DR   Pfam; PF08526; PAD_N; 1.
DR   PIRSF; PIRSF001247; Protein-arginine_deiminase; 1.
DR   SUPFAM; SSF110083; SSF110083; 1.
DR   SUPFAM; SSF49503; SSF49503; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Chromatin regulator; Citrullination;
KW   Complete proteome; Cytoplasm; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Nucleus; Polymorphism; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN         1    663       Protein-arginine deiminase type-4.
FT                                /FTId=PRO_0000220033.
FT   ACT_SITE    350    350       {ECO:0000269|PubMed:15247907}.
FT   ACT_SITE    471    471       {ECO:0000269|PubMed:15247907}.
FT   ACT_SITE    473    473       {ECO:0000269|PubMed:15247907}.
FT   ACT_SITE    645    645       {ECO:0000269|PubMed:15247907}.
FT   METAL       153    153       Calcium 1. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       155    155       Calcium 1. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       155    155       Calcium 2. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       157    157       Calcium 1. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       157    157       Calcium 2. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       165    165       Calcium 1. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       165    165       Calcium 3; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       168    168       Calcium 3. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       170    170       Calcium 3; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       176    176       Calcium 1. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       179    179       Calcium 1. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       179    179       Calcium 2. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       349    349       Calcium 4. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       351    351       Calcium 5. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       353    353       Calcium 4. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       369    369       Calcium 5. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       370    370       Calcium 5; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       373    373       Calcium 5. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       388    388       Calcium 2. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       407    407       Calcium 4; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       410    410       Calcium 4; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   METAL       411    411       Calcium 4. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:17002273}.
FT   BINDING     346    346       TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:22004374}.
FT   BINDING     369    369       TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:22004374}.
FT   BINDING     374    374       Substrate.
FT   BINDING     374    374       TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:22004374}.
FT   BINDING     471    471       TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:22004374}.
FT   BINDING     473    473       TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:22004374}.
FT   BINDING     639    639       Substrate; via carbonyl oxygen.
FT   BINDING     645    645       TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:22004374}.
FT   MOD_RES     205    205       Citrulline.
FT                                {ECO:0000269|PubMed:20201080}.
FT   MOD_RES     212    212       Citrulline.
FT                                {ECO:0000269|PubMed:20201080}.
FT   MOD_RES     218    218       Citrulline.
FT                                {ECO:0000269|PubMed:20201080}.
FT   MOD_RES     372    372       Citrulline.
FT                                {ECO:0000269|PubMed:20201080}.
FT   MOD_RES     374    374       Citrulline.
FT                                {ECO:0000269|PubMed:20201080}.
FT   MOD_RES     383    383       Citrulline.
FT                                {ECO:0000269|PubMed:20201080}.
FT   VARIANT       8      8       R -> H (in dbSNP:rs35381732).
FT                                /FTId=VAR_053560.
FT   VARIANT      55     55       G -> S (does not catalytic activity;
FT                                dbSNP:rs11203366).
FT                                {ECO:0000269|PubMed:10488123,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21245532}.
FT                                /FTId=VAR_020639.
FT   VARIANT      79     79       T -> M (in dbSNP:rs35809521).
FT                                /FTId=VAR_053561.
FT   VARIANT      82     82       V -> A (does not catalytic activity;
FT                                dbSNP:rs11203367).
FT                                {ECO:0000269|PubMed:10488123,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21245532}.
FT                                /FTId=VAR_020640.
FT   VARIANT      89     89       D -> N. {ECO:0000269|PubMed:15338034}.
FT                                /FTId=VAR_027401.
FT   VARIANT     102    102       P -> T (in dbSNP:rs34309058).
FT                                {ECO:0000269|PubMed:15338034}.
FT                                /FTId=VAR_027402.
FT   VARIANT     112    112       G -> A (does not catalytic activity;
FT                                dbSNP:rs874881).
FT                                {ECO:0000269|PubMed:10488123,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21245532}.
FT                                /FTId=VAR_020641.
FT   VARIANT     131    131       R -> T (in dbSNP:rs12733102).
FT                                {ECO:0000269|PubMed:15338034}.
FT                                /FTId=VAR_027403.
FT   VARIANT     164    164       M -> T (in dbSNP:rs11588132).
FT                                /FTId=VAR_027404.
FT   VARIANT     260    260       D -> N (in dbSNP:rs35903413).
FT                                /FTId=VAR_053562.
FT   VARIANT     275    275       S -> F (in dbSNP:rs1748020).
FT                                {ECO:0000269|PubMed:15087120}.
FT                                /FTId=VAR_020642.
FT   MUTAGEN     346    346       Q->A: Impaired binding of TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:21882827}.
FT   MUTAGEN     374    374       R->A: Strongly reduces enzymatic
FT                                activity. {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:21882827}.
FT   MUTAGEN     374    374       R->Q: Impaired binding of TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:15247907,
FT                                ECO:0000269|PubMed:16567635,
FT                                ECO:0000269|PubMed:21882827}.
FT   MUTAGEN     639    639       R->Q: Impaired binding of TDFA Inhibitor.
FT                                {ECO:0000269|PubMed:21882827}.
FT   MUTAGEN     645    645       C->A: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:15247907}.
FT   CONFLICT    149    149       I -> V (in Ref. 3; BAF83196).
FT                                {ECO:0000305}.
FT   CONFLICT    247    247       M -> T (in Ref. 3; BAG37357).
FT                                {ECO:0000305}.
FT   CONFLICT    657    657       K -> E (in Ref. 3; BAF83196).
FT                                {ECO:0000305}.
FT   STRAND        4      8       {ECO:0000244|PDB:2DEW}.
FT   STRAND       11     13       {ECO:0000244|PDB:2DEX}.
FT   STRAND       15     20       {ECO:0000244|PDB:2DEW}.
FT   STRAND       23     28       {ECO:0000244|PDB:2DEW}.
FT   HELIX        30     32       {ECO:0000244|PDB:4X8C}.
FT   STRAND       39     44       {ECO:0000244|PDB:2DEW}.
FT   STRAND       48     51       {ECO:0000244|PDB:2DEW}.
FT   STRAND       77     82       {ECO:0000244|PDB:2DEW}.
FT   STRAND       85     88       {ECO:0000244|PDB:1WD8}.
FT   STRAND       90     98       {ECO:0000244|PDB:2DEW}.
FT   STRAND      101    118       {ECO:0000244|PDB:2DEW}.
FT   STRAND      123    126       {ECO:0000244|PDB:3APM}.
FT   TURN        133    137       {ECO:0000244|PDB:4X8G}.
FT   STRAND      148    150       {ECO:0000244|PDB:2DEW}.
FT   STRAND      158    160       {ECO:0000244|PDB:3B1U}.
FT   HELIX       165    167       {ECO:0000244|PDB:2DEW}.
FT   STRAND      168    170       {ECO:0000244|PDB:2DEW}.
FT   HELIX       174    179       {ECO:0000244|PDB:2DEW}.
FT   STRAND      180    189       {ECO:0000244|PDB:2DEW}.
FT   HELIX       193    195       {ECO:0000244|PDB:2DEW}.
FT   STRAND      196    202       {ECO:0000244|PDB:2DEW}.
FT   TURN        205    207       {ECO:0000244|PDB:2DEW}.
FT   HELIX       208    210       {ECO:0000244|PDB:2DEW}.
FT   STRAND      211    215       {ECO:0000244|PDB:2DEW}.
FT   STRAND      226    230       {ECO:0000244|PDB:2DEW}.
FT   STRAND      233    238       {ECO:0000244|PDB:2DEW}.
FT   STRAND      242    253       {ECO:0000244|PDB:2DEW}.
FT   STRAND      263    273       {ECO:0000244|PDB:2DEW}.
FT   STRAND      277    279       {ECO:0000244|PDB:3B1U}.
FT   STRAND      282    293       {ECO:0000244|PDB:2DEW}.
FT   STRAND      305    310       {ECO:0000244|PDB:2DEW}.
FT   HELIX       317    329       {ECO:0000244|PDB:2DEW}.
FT   STRAND      333    336       {ECO:0000244|PDB:2DEW}.
FT   HELIX       339    342       {ECO:0000244|PDB:2DEW}.
FT   TURN        348    350       {ECO:0000244|PDB:2DEW}.
FT   STRAND      351    359       {ECO:0000244|PDB:2DEW}.
FT   STRAND      362    369       {ECO:0000244|PDB:2DEW}.
FT   TURN        375    377       {ECO:0000244|PDB:2DEW}.
FT   HELIX       378    383       {ECO:0000244|PDB:2DEW}.
FT   STRAND      389    393       {ECO:0000244|PDB:2DEW}.
FT   STRAND      397    399       {ECO:0000244|PDB:2DEW}.
FT   HELIX       403    405       {ECO:0000244|PDB:2DEW}.
FT   HELIX       407    409       {ECO:0000244|PDB:2DEW}.
FT   STRAND      410    412       {ECO:0000244|PDB:2DEW}.
FT   STRAND      415    418       {ECO:0000244|PDB:2DEW}.
FT   STRAND      421    423       {ECO:0000244|PDB:2DEW}.
FT   STRAND      428    432       {ECO:0000244|PDB:2DEW}.
FT   HELIX       445    453       {ECO:0000244|PDB:2DEW}.
FT   HELIX       455    457       {ECO:0000244|PDB:2DEX}.
FT   STRAND      460    463       {ECO:0000244|PDB:2DEW}.
FT   STRAND      467    469       {ECO:0000244|PDB:2DEW}.
FT   HELIX       472    474       {ECO:0000244|PDB:2DEW}.
FT   STRAND      476    480       {ECO:0000244|PDB:2DEW}.
FT   STRAND      482    484       {ECO:0000244|PDB:1WD8}.
FT   STRAND      486    493       {ECO:0000244|PDB:2DEW}.
FT   HELIX       494    506       {ECO:0000244|PDB:2DEW}.
FT   TURN        507    511       {ECO:0000244|PDB:3APM}.
FT   TURN        515    517       {ECO:0000244|PDB:2DEW}.
FT   STRAND      519    521       {ECO:0000244|PDB:1WDA}.
FT   HELIX       526    531       {ECO:0000244|PDB:2DEW}.
FT   HELIX       533    557       {ECO:0000244|PDB:2DEW}.
FT   HELIX       561    563       {ECO:0000244|PDB:2DEW}.
FT   STRAND      564    568       {ECO:0000244|PDB:2DEW}.
FT   STRAND      571    573       {ECO:0000244|PDB:2DEW}.
FT   HELIX       575    577       {ECO:0000244|PDB:2DEW}.
FT   STRAND      579    583       {ECO:0000244|PDB:2DEW}.
FT   STRAND      586    588       {ECO:0000244|PDB:4X8C}.
FT   STRAND      590    592       {ECO:0000244|PDB:2DEW}.
FT   STRAND      595    599       {ECO:0000244|PDB:2DEW}.
FT   STRAND      607    610       {ECO:0000244|PDB:2DEY}.
FT   HELIX       611    620       {ECO:0000244|PDB:2DEW}.
FT   HELIX       621    623       {ECO:0000244|PDB:2DEW}.
FT   STRAND      626    630       {ECO:0000244|PDB:2DEW}.
FT   TURN        633    636       {ECO:0000244|PDB:2DEW}.
FT   HELIX       637    639       {ECO:0000244|PDB:2DEW}.
FT   TURN        643    646       {ECO:0000244|PDB:2DEW}.
FT   STRAND      647    651       {ECO:0000244|PDB:2DEW}.
FT   HELIX       658    660       {ECO:0000244|PDB:2DEW}.
SQ   SEQUENCE   663 AA;  74079 MW;  79D7AF7B3D307A3B CRC64;
     MAQGTLIRVT PEQPTHAVCV LGTLTQLDIC SSAPEDCTSF SINASPGVVV DIAHGPPAKK
     KSTGSSTWPL DPGVEVTLTM KVASGSTGDQ KVQISYYGPK TPPVKALLYL TGVEISLCAD
     ITRTGKVKPT RAVKDQRTWT WGPCGQGAIL LVNCDRDNLE SSAMDCEDDE VLDSEDLQDM
     SLMTLSTKTP KDFFTNHTLV LHVARSEMDK VRVFQATRGK LSSKCSVVLG PKWPSHYLMV
     PGGKHNMDFY VEALAFPDTD FPGLITLTIS LLDTSNLELP EAVVFQDSVV FRVAPWIMTP
     NTQPPQEVYA CSIFENEDFL KSVTTLAMKA KCKLTICPEE ENMDDQWMQD EMEIGYIQAP
     HKTLPVVFDS PRNRGLKEFP IKRVMGPDFG YVTRGPQTGG ISGLDSFGNL EVSPPVTVRG
     KEYPLGRILF GDSCYPSNDS RQMHQALQDF LSAQQVQAPV KLYSDWLSVG HVDEFLSFVP
     APDRKGFRLL LASPRSCYKL FQEQQNEGHG EALLFEGIKK KKQQKIKNIL SNKTLREHNS
     FVERCIDWNR ELLKRELGLA ESDIIDIPQL FKLKEFSKAE AFFPNMVNML VLGKHLGIPK
     PFGPVINGRC CLEEKVCSLL EPLGLQCTFI NDFFTYHIRH GEVHCGTNVR RKPFSFKWWN
     MVP
//
